Literature DB >> 33086917

Multimorbidity among incident Finnish systemic lupus erythematosus patients during 2000-2017.

Simo Kariniemi1,2, Vappu Rantalaiho3,4, Lauri J Virta5, Kari Puolakka6, Tuulikki Sokka-Isler7,8, Pia Elfving2.   

Abstract

The objective of the study was to examine the risk of other morbidities among patients with systemic lupus erythematosus (SLE). A total of 1006 adult new-onset SLE patients were identified during 1.1.2000- 31.12.2014 from the register of Social Insurance Institution. For each case three general population controls matched according to age, sex and place of residence at the index day were sampled from the population register. Both groups were followed up from the index date until the end of 2017 or until death. The national register on specialized care was explored to gather broadly their 12 organ-specific morbidities, which were found among 91.2% of SLE patients and 66.7% of comparators. The rate ratio (RR) was elevated in almost all disease groups. Musculoskeletal, cardiovascular and genitourinary conditions were the most common comorbidities with RRs of 1.82 (1.68 to 1.97), 1.91 (1.76 to 2.08) and 1.91 (1.73 to 2.09), respectively. Men with SLE had a significantly higher risk for diseases of the genitourinary system and endocrine, nutritional and metabolic diseases compared to women with SLE. The risk of concurrent morbidities is essential to note in the care of SLE patients.

Entities:  

Keywords:  Systemic lupus erythematosus; cardiovascular disease; comorbidity; gender; morbidity

Year:  2020        PMID: 33086917      PMCID: PMC7768886          DOI: 10.1177/0961203320967102

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  42 in total

1.  Demographic differences in the development of lupus nephritis: a retrospective analysis.

Authors:  Victoria A Seligman; Raymond F Lum; Jean L Olson; Hongzhe Li; Lindsey A Criswell
Journal:  Am J Med       Date:  2002-06-15       Impact factor: 4.965

2.  Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999-2012.

Authors:  Frances Rees; Michael Doherty; Matthew Grainge; Peter Lanyon; Graham Davenport; Weiya Zhang
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-06       Impact factor: 4.794

3.  Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population.

Authors:  H Jonsson; O Nived; G Sturfelt
Journal:  Medicine (Baltimore)       Date:  1989-05       Impact factor: 1.889

4.  Systemic Lupus Erythematosus and Endothelial Dysfunction: A Close Relationship.

Authors:  Edoardo Sciatti; Ilaria Cavazzana; Enrico Vizzardi; Ivano Bonadei; Micaela Fredi; Mara Taraborelli; Romina Ferizi; Marco Metra; Angela Tincani; Franco Franceschini
Journal:  Curr Rheumatol Rev       Date:  2019

5.  Annual incidence and standardized incidence ratio of cerebrovascular accidents in patients with systemic lupus erythematosus.

Authors:  C C Mok; L Y Ho; C H To
Journal:  Scand J Rheumatol       Date:  2009       Impact factor: 3.641

6.  Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study.

Authors:  Elisheva Pokroy-Shapira; Ilana Gelernter; Yair Molad
Journal:  Clin Rheumatol       Date:  2014-02-19       Impact factor: 2.980

7.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.

Authors:  G Bertsias; J P A Ioannidis; J Boletis; S Bombardieri; R Cervera; C Dostal; J Font; I M Gilboe; F Houssiau; T Huizinga; D Isenberg; C G M Kallenberg; M Khamashta; J C Piette; M Schneider; J Smolen; G Sturfelt; A Tincani; R van Vollenhoven; C Gordon; D T Boumpas
Journal:  Ann Rheum Dis       Date:  2007-05-15       Impact factor: 19.103

8.  Allergic disorders in systemic lupus erythematosus: prevalence and family history.

Authors:  I Sekigawa; T Yoshiike; N Iida; H Hashimoto; H Ogawa
Journal:  Lupus       Date:  2002       Impact factor: 2.911

9.  Drugs used in incident systemic lupus erythematosus - results from the Finnish nationwide register 2000-2007.

Authors:  P Elfving; K Puolakka; H Kautiainen; L J Virta; T Pohjolainen; O Kaipiainen-Seppänen
Journal:  Lupus       Date:  2016-01-27       Impact factor: 2.911

10.  Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study.

Authors:  John G Hanly; Li Su; Murray B Urowitz; Juanita Romero-Diaz; Caroline Gordon; Sang-Cheol Bae; Sasha Bernatsky; Ann E Clarke; Daniel J Wallace; Joan T Merrill; David A Isenberg; Anisur Rahman; Ellen M Ginzler; Michelle Petri; Ian N Bruce; M A Dooley; Paul Fortin; Dafna D Gladman; Jorge Sanchez-Guerrero; Kristjan Steinsson; Rosalind Ramsey-Goldman; Munther A Khamashta; Cynthia Aranow; Graciela S Alarcón; Barri J Fessler; Susan Manzi; Ola Nived; Gunnar K Sturfelt; Asad A Zoma; Ronald F van Vollenhoven; Manuel Ramos-Casals; Guillermo Ruiz-Irastorza; S Sam Lim; Kenneth C Kalunian; Murat Inanc; Diane L Kamen; Christine A Peschken; Soren Jacobsen; Anca Askanase; Chris Theriault; Kara Thompson; Vernon Farewell
Journal:  Arthritis Rheumatol       Date:  2015-07       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.